Detail akcie Synlogic Rg online

Business Summary: Synlogic, Inc. is a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases. The Company is focused on rare metabolic disorders, with its lead program, labafenogene marselecobac (SYNB1934), studied in Synpheny-3, a global, pivotal Phase 3 study for patients with phenylketonuria (PKU), and SYNB1353, a potential treatment for homocystinuria (HCU). The Company's early-stage pipeline includes product candidates for enteric hyperoxaluria, gout, and cystinuria, and has been fueled by a reproducible, proprietary approach that creates gastrointestinal (GI)-restricted, oral medicines with new enzymatic pathways designed to consume or produce specific biological targets. The Company designs, develops and manufactures these drug candidates, which are produced by applying genetic engineering to well-characterized probiotics. The Company’s preclinical work includes additional metabolic disease research.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Synlogic Inc revenues decreased from $8K to $0K. Net loss decreased 89% to $2.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Discovery and development of synthetic biology therapeutics segment loss decrease of 93% to $2.7M.